Credit Suisse’s KalVista Pharmaceuticals KALV Stock Holding History

Credit Suisse’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$7	–	3522
2022 Q4	$7	Sell	1 -136	-99%	-$728	﹤0.01%	3779
2022 Q3	$2K	Buy	137 +113	+471%	+$1.58K	﹤0.01%	3736
2022 Q2	$0	Buy	+24	New	+$265	﹤0.01%	4128
2016 Q3	–	Sell	-2,015	Closed	-$18K	–	4178
2016 Q2	$18K	Buy	+2,015	New	+$23.3K	﹤0.01%	4176

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Credit Suisse's KALV Position: Q1 2023 in Review

Credit Suisse sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 1 share — an estimated $7 sold.

Credit Suisse first reported a position in KALV in Q2 2016 and held it in 4 quarters. The position peaked at $18K in Q2 2016. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Credit Suisse reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 1 KalVista Pharmaceuticals share in Q1 2023, an estimated $7.
Credit Suisse first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 4 quarters.
Credit Suisse's KalVista Pharmaceuticals position peaked at $18K in Q2 2016.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.